<div><div></div><div><span><ul><li><span>According to estimates from 11 analysts, Sutro Biopharma, Inc. stock's average price target has risen from $35.73 to $41.64, with forecasts ranging from $9 to $60 per share</span></li><li><span>Based on the May 14 closing price, the updated target implies approximately 8% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 0 Holds and 1 Sells</span></li></ul><p><span>Explore more price target data and ratings for Sutro Biopharma, Inc. on the </span><span>, and track all previous and future analyst recommendations for Sutro Biopharma, Inc. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

STRO

LABU

<p>Sutro Biopharma, Inc.'s stock price target has been raised from $35.73 to $41.64, indicating an 8% potential upside based on the May 14 closing price. The consensus rating remains a 'Buy' from 12 analysts, with 11 recommending 'Buy' and 1 'Sell'.</p>

TradingView

Sutro Biopharma

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Factset Research

Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside